JP2025501682A5 - - Google Patents

Info

Publication number
JP2025501682A5
JP2025501682A5 JP2024532799A JP2024532799A JP2025501682A5 JP 2025501682 A5 JP2025501682 A5 JP 2025501682A5 JP 2024532799 A JP2024532799 A JP 2024532799A JP 2024532799 A JP2024532799 A JP 2024532799A JP 2025501682 A5 JP2025501682 A5 JP 2025501682A5
Authority
JP
Japan
Prior art keywords
gapmer oligonucleotide
optionally
nucleoside
substitution group
gapmer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/051663 external-priority patent/WO2023102188A1/en
Publication of JP2025501682A publication Critical patent/JP2025501682A/ja
Publication of JP2025501682A5 publication Critical patent/JP2025501682A5/ja
Pending legal-status Critical Current

Links

JP2024532799A 2021-12-03 2022-12-02 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド Pending JP2025501682A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163285888P 2021-12-03 2021-12-03
US202163285665P 2021-12-03 2021-12-03
US202163285705P 2021-12-03 2021-12-03
US202163285696P 2021-12-03 2021-12-03
US202163285692P 2021-12-03 2021-12-03
US63/285,888 2021-12-03
US63/285,696 2021-12-03
US63/285,692 2021-12-03
US63/285,665 2021-12-03
US63/285,705 2021-12-03
PCT/US2022/051663 WO2023102188A1 (en) 2021-12-03 2022-12-02 Gapmer antisense oligonucleotides with modified backbone chemistries

Publications (2)

Publication Number Publication Date
JP2025501682A JP2025501682A (ja) 2025-01-23
JP2025501682A5 true JP2025501682A5 (enExample) 2026-06-23

Family

ID=86613042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532799A Pending JP2025501682A (ja) 2021-12-03 2022-12-02 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド

Country Status (5)

Country Link
EP (1) EP4441224A4 (enExample)
JP (1) JP2025501682A (enExample)
CN (1) CN119452086A (enExample)
CA (1) CA3241316A1 (enExample)
WO (1) WO2023102188A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023122762A1 (en) 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
CN119824089A (zh) * 2025-02-11 2025-04-15 西安浩瑞基因技术有限公司 引物组合及其在红绿色盲基因基因opn1lw和opn1mw基因分型中的用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014226A1 (en) 1992-12-14 1994-06-23 Honeywell Inc. Motor system with individually controlled redundant windings
EP1253199A1 (en) * 1993-09-02 2002-10-30 Ribozyme Pharmaceuticals, Inc. Abasic moieties containing enzymatic nucleic acids
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US8604183B2 (en) 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
MX2007010922A (es) * 2005-03-10 2007-10-12 Genentech Inc Metodos y composiciones para modular la integridad vascular.
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
CA2648585C (en) * 2006-04-07 2017-07-25 Idera Pharmaceuticals, Inc. Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
EP2505647A1 (en) * 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of DGAT2
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
DK2152879T3 (da) * 2007-05-01 2013-02-18 Santaris Pharma As RNA antagonistforbindelser til modulering af beta-catenin
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
KR101110013B1 (ko) * 2007-10-05 2012-02-29 (주)바이오니아 서열 내에 어베이직 부분을 포함하는 ｐｃｒ 증폭용프라이머
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
HK1200484A1 (zh) * 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
US20150247141A1 (en) * 2012-09-14 2015-09-03 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
CA2889044A1 (en) * 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
EP2959000B1 (en) * 2013-02-25 2018-08-15 Integrated DNA Technologies Inc. Naphthyl-azo modifications for antisense compounds
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2016024205A1 (en) * 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
KR20250112919A (ko) * 2015-12-21 2025-07-24 노파르티스 아게 타우 발현을 감소시키기 위한 조성물 및 방법
AU2019310097A1 (en) * 2018-07-25 2021-02-04 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ATXN2 expression
JP2022537581A (ja) * 2019-06-21 2022-08-26 クラリス コーポレーション Ｐｐｍ１阻害剤およびその使用方法

Similar Documents

Publication Publication Date Title
JP2024543214A5 (enExample)
JP2022536085A5 (enExample)
CN111373043B (zh) 用于降低snca表达的化合物和方法
US20250051766A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
JP6253590B2 (ja) Ｈｍｇｂ１断片を利用した脊髄の損傷に対する新規治療法
US20230125137A1 (en) Unc13a antisense oligonucleotides
TWI870557B (zh) 用於調節ｓｍｎ２之化合物及方法
EP1737438B1 (en) Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome
WO2023102242A2 (en) Splice switcher antisense oligonucleotides with modified backbone chemistries
JP2023507926A5 (enExample)
JP2023528435A5 (enExample)
CN119452086A (zh) 具有修饰的主链化学的gapmer反义寡核苷酸
JP2026504486A (ja) Ｐｉｋｆｙｖｅアンチセンスオリゴヌクレオチド
JP2025514346A (ja) Ｓｙｆ２アンチセンスオリゴヌクレオチド
CN106102733B (zh) 一种用于在治疗椎间盘相关性疼痛中使用的组合物
TWI818286B (zh) 包括表現腫瘤壞死因子可誘導基因６的間葉幹細胞之組成物及藥物組成物
CA2610413A1 (en) Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
JP2022071083A (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
JP2008184396A (ja) 神経損傷に起因する身体機能障害の予防及び治療のための医薬
Bertolín-Guillén et al. Serotonin syndrome due to association of venlafaxine, maprotiline and reboxetine
Rabie et al. Temporomandibular joint pathology and its indication in clinical orthodontics
Calvani et al. Personal orbicularis mouth muscle suspension technique for lip augmentation
US20240342175A1 (en) Compositions and Methods for Treating Spinal Cord Injury and Synaptic Dysfunction
CN120882871A (zh) 用于治疗神经系统病症的方法
TW202540422A (zh) 用於治療與ｕｂｅ３ａ過表現相關之疾患之組合物及方法